Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...

Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

The first patient has been treated in the pivotal Ideate-Lung02 trial of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage small cell lung cancer (SCLC), comparing ...

Some are leveraging Merck's partnership with Daiichi Sankyo to develop antibody drug conjugates ("ADCs"), a pioneering new type of dual action therapy (two candidates to date - ifinatamab ...

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Small-Cell Lung Cancer. According to... Likelihood of Approval and Phase Transition Success Rate ...

00:10 | From the World Congress on Lung Cancer, some exciting data were recently presented by Charles Rudin regarding an antibody drug conjugate [ADC], I believe is pronounced ifinatamab deruxtecan [I ...